Richard A. Heyman Sells 1,270 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman sold 1,270 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $19.99, for a total transaction of $25,387.30. Following the completion of the sale, the director now directly owns 137,155 shares of the company’s stock, valued at $2,741,728.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Enliven Therapeutics Trading Down 6.3 %

Shares of Enliven Therapeutics stock opened at $18.69 on Wednesday. The firm has a fifty day simple moving average of $16.94 and a 200-day simple moving average of $14.29. Enliven Therapeutics, Inc. has a 1-year low of $9.80 and a 1-year high of $26.00. The stock has a market capitalization of $770.03 million, a price-to-earnings ratio of -8.53 and a beta of 1.06.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09. As a group, research analysts predict that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current year.

Analyst Ratings Changes

Separately, Mizuho started coverage on shares of Enliven Therapeutics in a research report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 target price for the company.

Institutional Trading of Enliven Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ELVN. AJOVista LLC acquired a new position in Enliven Therapeutics during the 4th quarter valued at $28,000. Tower Research Capital LLC TRC acquired a new position in Enliven Therapeutics during the 1st quarter valued at $36,000. Ameritas Investment Partners Inc. acquired a new position in Enliven Therapeutics during the 2nd quarter valued at $39,000. Royal Bank of Canada raised its stake in Enliven Therapeutics by 532.7% during the 2nd quarter. Royal Bank of Canada now owns 3,075 shares of the company’s stock valued at $63,000 after purchasing an additional 2,589 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Enliven Therapeutics during the 4th quarter valued at $66,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.